Exchange: NASDAQ·Updated 07:54 PM EDT

TPST News

News
all
press releases
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers DataMEDS AI (NASDAQ:MEDS) shares rose 124.1% to $3.63 during Wednesday's pre-market session. The company's market cap stands at $4.9 million. Tempest Therapeutics (NASDAQ:TPST) stock moved upwards byread more...
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers DataMEDS AI (NASDAQ:MEDS) shares rose 124.1% to $3.63 during Wednesday's pre-market session. The company's market cap stands at $4.9 million. Tempest Therapeutics (NASDAQ:TPST) stock moved upwards byread more...
Benzinga
More News
Tempest Doubles Down on In Vivo CAR-T with Second Delivery Platform
Tempest Therapeutics (NASDAQ:TPST) is moving aggressively to build a multi-platform in vivo CAR-T business, securing an exclusive option to license a clinical-stage CD7-targeted lentiviral technology just months before its own next-generation CAR-T program is expected to enter the clinic.
24-7 Market News
Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket
Tempest shares surged 49.6% on a Senlang CD7 CAR-T option deal, while several small-cap stocks posted sharp premarket gains and losses.read more...
Benzinga
Tempest Therapeutics (TPST) Stock Climbs Over 66% After Hours: Here's Why
Tempest Therapeutics shares soared 66.53% after hours Tuesday following an exclusive option agreement expanding its in vivo CAR-T pipeline.read more...
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Tempest Therapeutics (NASDAQ:TPST) stock increased by 41.6% to $1.07 during Tuesday's after-market session. The company's market cap stands at $12.9 million. Jupiter Neurosciences (NASDAQ:JUNS) stockread more...
Benzinga
New Strong Buy Stocks for April 10th
ESCA, GRDN, TPST, ASTE and ECG have been added to the Zacks Rank #1 (Strong Buy) List on April 10th, 2026.
Zacks
Tempest Therapeutics (NASDAQ:TPST) CEO Matthew Angel Acquires 231,482 Shares
Tempest Therapeutics, Inc. (NASDAQ:TPST - Get Free Report) CEO Matthew Angel acquired 231,482 shares of the business's stock in a transaction on Tuesday, March 24th. The shares were purchased at an average cost of $2.16 per share, for a total transaction of $500,001.12. Following the completion of...
MarketBeat
TPST Stock Plummets After Inking Deal To Acquire CAR-T Programs From Privately-Held Firm In All-Stock Transaction
The transaction is expected to close in early 2026, provided it receives all required approvals.
Stocktwits
Why Tempest Therapeutics (TPST) Stock Is Down 45% Today
Tempest Therapeutics shares fell Wednesday after the announcement of an all-stock acquisition of dual-CAR T programs from Factor Bioscience.read more...
Benzinga
TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy
Zacks

Advertisement|Remove ads.